Assessing the Eligibility Criteria in Phase III Randomized Controlled Trials of Drug Therapy in Heart Failure With Preserved Ejection Fraction: The Critical Play-Off Between a "Pure" Patient Phenotype and the Generalizability of Trial Findings.

doi:10.1016/j.cardfail.2017.04.006

Article

Assessing the Eligibility Criteria in Phase III Randomized Controlled Trials of Drug Therapy in Heart Failure With Preserved Ejection Fraction: The Critical Play-Off Between a "Pure" Patient Phenotype and the Generalizability of Trial Findings.

Journal of cardiac failure - 1 Jul 2017

Patel Hitesh C, Hayward Carl, Dungu Jason N, Papadopoulou Sofia, Saidmeerasah Abdel, Ray Robin, Di Mario Carlo, Shanmugam Nesan, Cowie Martin R, Anderson Lisa J

Abstract excerpt

AIMS: To investigate the effect of the different eligibility criteria used by phase III clinical studies in heart failure with preserved ejection fraction (HFpEF) on patient selection, phenotype, and survival. METHODS AND RESULTS: We applied the key eligibility criteria of 7 phase III HFpEF studies (Digitalis Investigation Group Ancillary, Candesartan in Patients With Chronic Heart Failure and Preserved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Assessing the Eligibility Criteria in Phase III Randomized Controlled Trials of Drug Therapy in Heart Failure With Preserved Ejection Fraction: The Critical Play-Off Between a "Pure" Patient Phenotype and the Generalizability of Trial Findings.

Abstract excerpt

Topics

Related research